T1	Participants 134 315	Nearly 2000 patients with stage IIB and III melanoma have participated in four multicenter, randomized trials, conducted by the Eastern Cooperative Oncology Group and the Intergroup
T2	Participants 697 739	patients in E1684, E1690, E1694, and E2696
T3	Participants 819 868	713 patients randomized to high-dose IFN-alpha 2b
T4	Participants 1729 1773	In patients with high-risk resected melanoma
